Company Overview

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on the development, acquisition, and commercialization of branded and generic prescription dermatology products. The company operates within the specialty pharmaceuticals and dermatology therapeutics industries, targeting chronic and acute skin conditions that are typically managed by dermatologists and other healthcare providers. Journey Medical’s business model emphasizes in-licensing, lifecycle management, and targeted commercialization rather than large-scale drug discovery.

The company’s primary revenue drivers are its portfolio of FDA-approved dermatology products, which address conditions such as acne, hyperhidrosis, rosacea, fungal infections, and inflammatory skin diseases. Journey Medical is majority-owned by Fortress Biotech, Inc., which provides strategic, financial, and operational support. The company was founded in 2014 and has evolved from a product acquisition platform into a focused dermatology commercial organization with an established U.S. sales infrastructure.

Business Operations

Journey Medical generates revenue through the U.S. commercialization of prescription dermatology products marketed to dermatologists, pediatricians, and other specialty healthcare providers. Its operations are primarily organized around its dermatology product portfolio, which includes both branded products and authorized generics acquired or licensed from third parties. Sales are driven through a dedicated specialty sales force and supported by medical education and market access initiatives.

The company’s operations are predominantly domestic, with commercial activity concentrated in the United States. Journey Medical does not conduct large-scale manufacturing internally; instead, it relies on third-party manufacturers and supply chain partners. As a subsidiary of Fortress Biotech, Inc., Journey Medical benefits from shared services, capital access, and strategic oversight, while maintaining operational independence in product commercialization.

Strategic Position & Investments

Journey Medical’s strategic direction centers on expanding its dermatology portfolio through selective acquisitions, in-licensing agreements, and lifecycle optimization of existing products. The company prioritizes assets that are already FDA-approved or late-stage, reducing development risk and accelerating time to revenue. Growth initiatives include label expansions, new dosage forms, and targeted promotional strategies within established dermatology markets.

As part of the Fortress Biotech, Inc. ecosystem, Journey Medical has access to capital and a pipeline of potential product candidates sourced through Fortress’s broader biopharmaceutical platform. The company has historically invested in products addressing underserved or niche dermatologic indications where focused sales execution can generate sustainable cash flows. Data on certain early-stage or prospective investments is inconclusive based on available public sources.

Geographic Footprint

Journey Medical is headquartered in the United States and conducts the majority of its business activities domestically. Its commercial footprint is centered on U.S. dermatology clinics and specialty healthcare providers, supported by a nationwide sales and distribution network. The company does not currently report material direct commercial operations outside the U.S.

International exposure is primarily indirect, through licensing arrangements or supply chain relationships rather than owned subsidiaries or foreign commercial teams. As a result, Journey Medical’s geographic influence remains concentrated in North America, with limited disclosed operational presence in other regions based on available public information.

Leadership & Governance

Journey Medical is led by an experienced management team with backgrounds in specialty pharmaceuticals, dermatology commercialization, and corporate strategy. The company’s leadership emphasizes disciplined capital allocation, portfolio optimization, and leveraging the strategic resources of Fortress Biotech, Inc. to drive shareholder value.

Key executives include:

• Claude Maraoui – President and Chief Executive Officer
• Michael Dragone – Chief Financial Officer
• David Thompson – Chief Operating Officer
• Michael Phelps – Senior Vice President, Sales

The company’s governance structure is closely aligned with its parent organization, Fortress Biotech, Inc., which maintains majority ownership and board representation. Leadership philosophy centers on opportunistic product acquisition, efficient commercialization, and maintaining a focused presence within the dermatology specialty market.